Each female sets her experience of 47 manifestations on a 6 point scale separately for the premenstrual, menstrual and intermenstrual phases of her latest and worst menstrual cycle. Daily Symptoms Report will be filled at the start and at end of the study (before and after performing swimming exercise) Females in group I will be instructed to engage into 12 classes of 60-minute Zumba® fitness over an 8-week period.

Each female sets her experience of 47 manifestations on a 6 point scale separately for the premenstrual, menstrual and intermenstrual phases of her latest and worst menstrual cycle. Daily Symptoms Report will be filled at the start and at end of the study (before and after performing swimming exercise) Females in group I will be instructed to engage into 12 classes of 60-minute Zumba® fitness over an 8-week period Each class was one hour in length and a recovery period of at least 48 hours will be taken between classes. The Zumba® fitness scheduling of sessions will be self-selected by the participants. The Zumba sessions will be conducted at a fitness center (SAMIA ALLOUBA gym and fitness center) and will consist of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the first 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certified Zumba instructors, each responsible for regular sessions per week.

Inclusion Criteria:

1. Age:18-25 years.
2. BMI :18-25 kg/m2.
3. A regular menstrual cycle of 23-35 days duration.
4. No previous practice of Zumba.
5. Free from musculoskeletal injury.
6. All women did not use oral contraceptive pills or any psychotropic agents.

Exclusion Criteria:

1. Pregnancy.
2. Metabolic/cardiorespiratory contraindications to physical exercise.
3. Cigarette smokers.
4. Recovering from a major injury or illness; or using anti-inflammatory, hyperlipidemia or hypertension medication.
5. any abnormality in ovulation or those with pelvic inflammatory diseases (PID) or a history of endometriosis.
6. Women with endocrine abnormality as diabetes mellitus, thyroid, pituitary, or ovarian disorders.
7. Women who are taking any hormonal drugs or drugs that affect hormones as antidepressant drugs during the preceding three months before the study.